Anticipated initial collaboration term.

No definition available.

Name:	idra_AnticipatedInitialCollaborationTerm
Namespace Prefix:	idra_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of common stock ownership under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	idra_CommonStockOwnershipPercentage
Namespace Prefix:	idra_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial research period.

+ References

No definition available.

+ Details

Name:	idra_ExpectedAgreementTerm
Namespace Prefix:	idra_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of optional additional targets.

+ References

No definition available.

+ Details

Name:	idra_NumberOfAdditionalTargetOptional
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of board director seats held.

+ References

No definition available.

+ Details

Name:	idra_NumberOfBoardOfDirectorSeatsHeld
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of common board of directors.

+ References

No definition available.

+ Details

Name:	idra_NumberOfCommonBoardOfDirectors
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of development candidates.

+ References

No definition available.

+ Details

Name:	idra_NumberOfDevelopmentCandidates
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of units of accounting in connection of agreements.

+ References

No definition available.

+ Details

Name:	idra_NumberOfUnitsOfAccountingInConnectionOfAgreements
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments made or expected to be made pursuant to the companion diagnostic agreement.

+ References

No definition available.

+ Details

Name:	idra_PaymentsPursuantToCompanionDiagnosticAgreement
Namespace Prefix:	idra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum royalty percentage on net sales.

+ References

No definition available.

+ Details

Name:	idra_PercentageOfMaximumRoyaltyOnNetSales
Namespace Prefix:	idra_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The remaining performance obligations under the agreement

+ References

No definition available.

+ Details

Name:	idra_RemainingPerformanceObligations
Namespace Prefix:	idra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments that may be received under collaboration agreements.

+ References

No definition available.

+ Details

Name:	idra_RevenueRecognitionMilestoneMethodMaximumMilestonePayments
Namespace Prefix:	idra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The revised, increased research period.

+ References

No definition available.

+ Details

Name:	idra_RevisedResearchAgreementTerm
Namespace Prefix:	idra_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The total number of board director seats.

+ References

No definition available.

+ Details

Name:	idra_TotalNumberOfBoardOfdirectorSeats
Namespace Prefix:	idra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The upfront, non-refundable, non-creditable cash payment received under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	idra_UpfrontPaymentReceivedUnderCollaboration
Namespace Prefix:	idra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=idra_BakerBrosAdvisorsLpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=idra_AbbottMolecularMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=idra_GskAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idra_LicenseResearchClinicalDevelopmentAndCommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idra_ResearchAndDevelopmentPlansAndDesignationOfDevelopmentCandidatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idra_ClinicalAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=idra_VivelixPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	idra_PharmaceuticalBackupCompoundsAxis=idra_BackupCompoundMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idra_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idra_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=idra_UpFrontPaymentsArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	idra_AccountingUnitsAxis=idra_RAndDServicesUnitOfAccountingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	idra_AccountingUnitsAxis=idra_JSCDeliverableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements (Details) $ in Thousands	1 Months Ended			3 Months Ended	12 Months Ended
	Nov. 30, 2016 USD ($) director	Nov. 30, 2015 USD ($) item person	May 31, 2014 USD ($)	Jun. 30, 2017	Dec. 31, 2017 USD ($) item	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Remaining performance obligation					$ 0
Number of board director seats held \| director	2
Total number of board director seats \| director	7
Number of common board of directors \| director	0
Collaboration revenue					902	$ 16,199	$ 249
Current portion of deferred revenue					566	1,111
long-term deferred revenue						152
Expenses					67,369	54,956	49,095
Baker Bros. Advisors LP
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Common stock ownership percentage under the collaboration agreement	7.00%
Abbott Molecular
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Paid or expects to pay for external development expenses			$ 6,700
Expenses					800	400	900
Expected agreement term			5 years
GSK Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Number of optional additional targets \| person		2
Number of development candidates \| person		1
Number of units of accounting in connection of agreements \| item		2
Remaining performance obligation					$ 0
Maximum royalty percentage on net sales					5.00%
Deferred revenue					$ 900	1,100	100
Expected agreement term		27 months
Revised, increased research period				36 months
GSK Agreement \| License, Research, Clinical Development and Commercialization
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments		$ 100,000			20,000
GSK Agreement \| Research and Development Plans and Designation of Development Candidates
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments		9,000			1,000
GSK Agreement \| Clinical and Commercial Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments		$ 89,000			$ 17,000
GSK Agreement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Anticipated initial collaboration term		4 years
Number of optional additional targets \| item					2
GSK Agreement \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Anticipated initial collaboration term		2 years
Vivelix
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Number of units of accounting in connection of agreements \| item					3
Number of board director seats held \| director	2
Total number of board director seats \| director	4
Number of common board of directors \| director	0
Collaboration revenue						$ 15,000	$ 0
Vivelix \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	$ 140,000
Collaboration revenue					$ 100
Vivelix \| Maximum \| Back-up compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Anticipated initial collaboration term	3 years
Milestone payments	$ 52,500
Vivelix \| Maximum \| Development and Regulatory Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	65,000
Vivelix \| Maximum \| Development and Regulatory Milestones \| Back-up compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	35,000
Vivelix \| Maximum \| Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	75,000
Vivelix \| Maximum \| Sales Milestones \| Back-up compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	17,500
Up-front Payment Arrangement \| GSK Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment received under collaboration agreement		$ 2,500
Up-front Payment Arrangement \| Vivelix
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment received under collaboration agreement	$ 15,000
R&D Services Unit of Accounting \| GSK Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment received under collaboration agreement		2,500
JSC Deliverable \| GSK Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment received under collaboration agreement		$ 0